


INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Christopher Reading et al.	
	FILING DATE December 5, 2003	ART UNIT 1614

Sheet 1 of 1

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
BK	2,920,099	01-12-60	Agnello et al.			
	3,523,942	08-11-70	Holden			
	3,558,608	01-26-71	Klimstra			
	3,705,150	12-05-72	Tuba et al.			
	3,983,111	09-28-76	Phillipps et al.			
	3,998,829	12-21-76	Phillips et al.			
	4,191,759	03-04-80	Johnston et al.			
	4,197,296	04-08-80	Phillipps et al.			
	4,330,539	05-18-82	Sleigh et al.			
	4,360,663	11-23-82	Asano et al.			
	4,435,327	03-06-84	Petzoldt et al.			
	4,456,602	06-26-84	Anderson et al.			


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
BK	WO 87/01706	03-26-87	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 08/07/2006
<small>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY WITH NEXT COMMUNICATION TO APPLICANT.</small>	



SHEET 1 OF 3

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Reading, et al.	
	FILING DATE December 5, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BK	2,108,646	2-15-38	Bockmühl et al.			
	2,170,124	8-22-39	Butenandt et al.			
	2,267,257	12-23-41	Ruzcika			
	2,286,892	6-16-42	Bockmühl et al.			
	2,531,441	11-28-50	Julian et al.			
	2,561,378	7-24-51	Julian et al.			
	2,566,336	9-04-51	Julian et al.			
	2,582,258	1-15-52	Julian et al.			
	2,697,107	12-14-51	Ruschig et al.			
	2,705,238	3-29-55	Julian et al.			
	2,843,609	7-17-58	Colton			
	2,845,381	7-29-58	Tindall			
	2,878,267	3-17-59	Szpilfogel et al.			
	2,880,212	3-31-59	Grob et al.			
	2,894,958	7-14-59	Goldberg et al.			
	2,908,696	10-13-59	Nussbaum et al.			
	2,911,418	11-03-59	Johns et al.			
	2,927,119	3-01-60	Ellis et al.			
	3,001,988	9-26-61	Nysted			
	3,004,968	10-17-61	Jeger et al.			
	3,018,298	1-23-62	Klimstra et al.			
	3,060,203	10-23-62	Huffman			
	3,084,156	4-02-63	Counsell et al.			
	3,101,358	4-20-63	De Ruggieri et al.			
↓	3,107,254	10-15-63	Lednicer	↓	↓	

EXAMINER /Brian-Yong Kwon/	DATE CONSIDERED 08/07/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Reading, et al.	
	FILING DATE December 5, 2003	GROUP 1614


U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BK	3,124,571	3-10-64	Ringold et al.			
	3,148,198	9-08-64	Goldcamp et al.			
	3,189,597	6-15-65	Belding et al.			
	3,189,623	6-15-65	Ayer			
	3,264,329	8-02-66	Clark et al.			
	3,281,431	10-25-66	Sollman			
	3,282,969	11-01-66	Boswell			
	3,301,872	1-31-67	Sollman			
	3,324,001	6-06-67	Bertin et al.			
	3,325,535	6-13-67	Holden et al.			
	3,345,385	10-03-67	Nagata			
	3,357,888	12-12-67	Campbell et al.			
	3,380,886	4-30-68	Campbell et al.			
	3,427,300	2-11-69	Sarett et al.			
	3,436,390	4-01-69	Lefebvre et al.			
	3,673,173	6-27-72	Komeno et al.			
	3,691,207	09-12-72	Klimstra			
	3,738,983	6-12-73	Dryden et al.			
	3,780,073	12-18-73	Shroff			
	3,787,453	1-22-74	Fahrenholtz			
	3,816,480	6-11-74	Lenz			
	3,872,076	3-18-78	Rosen			
	3,917,831	11-4-75	Grunwell et al.			
	3,943,124	3-9-76	Phillipps et al.			
	3,944,576	3-16-76	van den Broek et al.			
	3,987,055	10-19-76	Berlin et al.			
	4,908,358	3-13-90	Schrieber			

EXAMINER	/Brian-Yong Kwon/	DATE CONSIDERED	08/07/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Reading, et al.	
	FILING DATE December 5, 2003	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES)
BK	Antin, J., et al., Cytokine dysregulation and acute graft-versus-host disease, <i>Blood</i> , 80(12):2964-2968 1992
	Arsenou, E.S., et al., Optimization of the allylic oxidation in the synthesis of 7-keto- Δ^5 -steroidal substrates, <i>Steroids</i> , 68:407-414 2003
	Counsell, R.E., et al., Hypocholesterolemic Agents. III. N-Methyl-N-(dialkylamino)alkyl-17 β -aminoandrost-5-en-3 β -ol derivatives, <i>J. Med. Pharm. Chem.</i> , 5:1224-1233 1962
	Greinix, H., et al., Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study, <i>Blood</i> , 96(7):2426-2431 2000
	Hervé, P., et al., Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease, <i>Blood</i> , 79(12):3362-3368 1992
	Lu, M.C., et al., Inhibition of cholesterol side-chain cleavage. 4. Synthesis of A or B ring modified azacholesterols, <i>J. Med. Chem.</i> , 24:1038-1042 1981
	Martin, P.J., et al., A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment, <i>Blood</i> , 77(8):1821-1828 1991
	Ratanatharathorn, V., et al., Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease, <i>Ann Int Med</i> , 133(4):275-279 2000
	Vogelsang, G.B., How I treat chronic graft-versus-host disease, <i>Blood</i> , 97(5):1196-1201 2001
V	Weisdorf, D., et al., Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome, <i>Blood</i> , 75(4):1024-1030 1990

EXAMINER	/Brian-Yong Kwon/	DATE CONSIDERED	08/07/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.14APPLICATION NO.
10/728,400INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Reading, et al.FILING DATE
12/05/03GROUP
1614

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BK	3,080,360	03/05/63	Pappo			
	3,137,710	06/16/64	de Ruggieri, et al			
	3,153,063	10/13/64	de Ruggieri, et al			
	3,155,690	11/03/64	Cole			
	3,264,326	08/02/66	Clark, et al			
	3,631,033	12/28/71	Nathansohn, et al			
	4,412,953	11/01/83	Winters			
	4,898,694	02/06/90	Schwartz, et al			
	5,077,284	12/31/91	Loria, et al			
	5,206,008	04/27/93	Loria			
	5,277,907	01/11/94	Loria			
	5,387,583	02/07/95	Loria			
	5,461,042	10/24/95	Loria			
	5,478,566	12/26/95	Loria			
	5,585,371	12/17/96	Lardy			
	5,635,496	06/03/97	Daynes, et al			
	5,641,766	06/24/97	Loria			
	5,641,768	06/24/97	Lardy			
	5,686,438	11/11/97	Daynes, et al			
	5,707,983	01/13/98	Lardy			
	5,811,418	09/22/98	Daynes, et al			
	5,827,841	10/27/98	Daynes, et al			
	5,885,977	03/23/99	Pauza, et al			
	5,977,095	11/02/99	Araneo, et al			
	6,187,767 B1	02/13/01	Araneo, et al			
	6,432,940	08/13/02	Labrie			

EXAMINER

/Brian-Yong Kwon/

DATE CONSIDERED

08/07/2006

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
	APPLICANT Reading, et al.	
	FILING DATE 12/05/03	GROUP 1614

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BK	2003-0060425 A1	Ahlem, et al			
↓	2003-0083231 A1	Ahlem, et al			
	2004-0043973 A1	Ahlem, et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BK	Arth, G., et al., "Steroidal androgen biosynthesis inhibitors", <i>J. Med. Chem.</i> , Vol. 14(8), pp. 675-79, (1971).
↓	Belovsky, O., et al., "Inhibition of glucose-6-phosphate dehydrogenase by steroids -VIII: Effects of synthetic C ₁₉ and C ₂₀ steroids upon placental glucose-6-phosphate dehydrogenase", <i>J. of Steroid Biochemistry</i> , Vol. 5, pp. 697-700, (1974).
	Chavis, C., et al., "New steroidal nitrosoureas", <i>Steroids</i> , Vol. 39 (2), pp. 129-47, (1982).
	Chavis, C., et al., "N.M>R. studies of D-Ribosylamines in solution: Derivatives of primary amines", <i>Carbohydrate Research</i> , 113, pp. 1-20, (1983).
	Davis, M., et al, "Steroid Amines. Part II. 17 α -aminoandrostane derivatives", <i>J. Chem. Soc.</i> , pp. 1698-1700, (1966).
	Flouret, G., et al., "17-aminocyclamido-5-androsten-3 β -ols", <i>J. Med Chem</i> , Vol. 11, pp. 880-82(1968).
	Hewett, C., et al., "Amino-steroids. Part IV. 16 β -morpholino-17-oxo- and 17 β -morpholino-16-oxo-5 α -androstanes", <i>J. Chem. Soc.</i> , pp. 1880-83, (1969)
	Hussain, A., et al, "Testosterone 17 β -N, N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone", <i>J. Pharmaceutical Sciences</i> , Vol. 91, pp. 785-89, (2002).
	Imrscher, K., et al., "Cholesterol analogues with OXA and OXA-AZA side chain a novel class of inhibitors of cholesterol biosynthesis", <i>Steroids</i> , Vol. 7(6), pp. 557-76, (1966).
	Johnson, K., et al., "Solution kinetics of a water soluble hydrocortisone prodrug: Hydrocortisone-21-lysinate", <i>J. of Pharmaceutical Sciences</i> , Vol 74(1), pp. 87-89, (1985).
	Jones, J., et al., "Steroids and steroidases. 10. Studies on some potentially antitumor active androstane compounds containing C-17 nitrogen mustard functionx", <i>J. of Med. Chem.</i> , Vol 14 (9), pp. 827-33, (1971).
↓	Kabara, J., et al, "Structure-function activity of azasterols and nitrogen-containing steroids", <i>Lipids</i> , Vol. 11(10), pp. 755-62, (1976).
	Kuehne, M., et al, "Steroidal dihydro-1,3-oxazines as antitumor agents", <i>J. Med. Pharm. Chem.</i> , 5, pp. 281-96, (1962)

EXAMINER	/Brian-Yong Kwon/	DATE CONSIDERED	08/07/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Reading, et al.	
		FILING DATE 12/05/03	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
BK	Lu, M., et al., "Inhibition of cholesterol side-chain cleavage. 4. Synthesis of A or B ring modified azacholesterols", <i>J. Med. Chem.</i> , 24, pp. 1038-42, (1981).
	Machkova, Z., et al., "Preparation of some amidic 6-ketosteroids as potential inhibitors of postecdysial cuticle sclerotization in <i>pyrrhocoris apterus</i> L", <i>Collect Czech Chem Commun</i> , Vol 39, pp 1091-97, (1974)
	Mahler, H., et al., "Nucleic acid interactions. VI. Effects of steroidal diamines", <i>Nucleic Acid Interactions</i> , Vol. 5 (7), pp. 2177-91, (1966).
	Matoba, K., et al., "Syntheses of Vitamin D analogues I", <i>Chem. Phar. Bull.</i> , (30 (12, pp. 4596-96, (1982).
	Mokotoff, M., et al, "Peptidyl aminosteroids as potential new antiarrhythmic agents", <i>Steroids</i> , Vol. 55, pp. 399-404, (1990).
	Pettit, G., et al., "Structural biochemistry. IV. 3 β -hydroxy-17 β -(L-prolyl) amino-androst-5-ene ¹⁻³ⁿ ", <i>Canadian J. of Chem.</i> , Vol 45, pp502-07, (1967).
	Robinson, C., et al., "The synthesis of 17 α -amino-5-androsten-3 β -ol; N.M.R. spectra of 17-substituted androstanes", <i>Steroids</i> , 6(5), pp.509-18, (1965).
	Schreck, R., et al, "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1" <i>Embo J</i> , 10, pp. 2247-58, (1991).
	Singh, H., et al., "Steroids & related studies: Part 82 - chandonium related azasteroidal neuromuscular blockers", <i>Indian J. of chem.</i> , Vol. 27B, pp. 508-12, (1988).
	Vincze, I., et al, "Steroids 54: Amino acylamidosteroids", <i>Steroids</i> , 61, pp. 697-702, (1996).
	Wheeler, O., et al., "Steroid derivatives of cysteamine and cysteine", <i>Canadian J. of Chem.</i> , Vol 47, pp. 160-62, (1969).
	Whitnall, M., et al, "Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice", <i>Intl. J. or Immunopharmacology</i> , 22, pp. 1 - 14, (2000).
	Zheng, G, et al., "Tricarbocyanine cholesteryl laureates labeled LDL: New near infrared fluorescent probes (NIRFs) for monitoring tumors and gene therapy of familial hypercholesterolemia", <i>Bioorganic & Med Chem Letters</i> , 12, pp. 1485-88, (2002).

EXAMINER	/Brian-Yong Kwon/	DATE CONSIDERED	08/07/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			